Today, the CEO of Arrowhead Research (ARWR), Christopher Richard Anzalone, sold shares of ARWR for $965K.
Following Christopher Richard Anzalone’s last ARWR Sell transaction on July 05, 2016, the stock climbed by 14.6%. This is Anzalone’s first Sell trade following 4 Buy transactions.
See today’s analyst top recommended stocks >>
Based on Arrowhead Research’s latest earnings report for the quarter ending December 31, the company posted quarterly revenue of $34.66 million and quarterly net profit of $12.04 million. In comparison, last year the company earned revenue of $650.1K and had a GAAP net loss of $14.88 million. Currently, Arrowhead Research has an average volume of 2.04M. The Company has a Price to Book ratio of 10.7522.
Based on 3 analyst ratings, the analyst consensus is Strong Buy with an average price target of $22.83, reflecting a 14.3% upside.
The insider sentiment on Arrowhead Research has been negative according to 41 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Arrowhead Pharmaceuticals, Inc. operates as a biopharmaceutical company. It develops medicines that treat intractable diseases by silencing the genes that cause them. The company was founded by R. Bruce Stewart in 1989 and is headquartered in Pasadena, CA.
